Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/16161
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLau, Lawrence F-
dc.contributor.authorMurone, Carmel-
dc.contributor.authorWilliams, David S-
dc.contributor.authorStandish, Richard-
dc.contributor.authorLee, Sze Ting-
dc.contributor.authorChristophi, Christopher-
dc.contributor.authorScott, Andrew M-
dc.contributor.authorMuralidharan, Vijayaragavan-
dc.date2016-07-24-
dc.date.accessioned2016-08-26T00:14:43Z-
dc.date.available2016-08-26T00:14:43Z-
dc.date.issued2016-07-24-
dc.identifier.citationANZ Journal of Surgery 2016; online first: 24 Julyen_US
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/16161-
dc.description.abstractBACKGROUND: Tumour metabolic response to chemotherapy is increasingly recognized as a prognostic indicator for colorectal cancer liver metastases (CRCLM). However, its clinical role and the underlying biological mechanism of its prognostic ability are unclear. This study compares metabolic to pathologic response for CRCLM, and correlates metabolic response to tumour expression of six key biomarkers. METHODS: Thirty-seven patients who had positron emission tomography imaging before and after pre-operative chemotherapy prior to liver resection for CRCLM were included. Metabolic response was assessed according to the positron emission tomography response criteria in solid tumours (PERCIST) and correlated to recurrence-free and overall survival. PERCIST was compared to tumour regression grading, computed tomography (CT) response, tumour necrosis and mucin and immunohistochemical expression of Ki-67, hypoxia inducible factor 1α, vascular endothelial growth factor, p53, p16 and vimentin. Area under the receiver operating characteristic curve (AUC), Kaplan-Meier survival, Spearman's correlation (rs ) and multivariate Cox regression analyses were used. RESULTS: PERCIST correlated significantly to 2-year mortality (AUC = 0.162, P < 0.01) and 2-year recurrence (AUC = 0.284, P = 0.03). Metabolically responsive tumours conferred a better overall survival (P = 0.01) and recurrence-free survival (P = 0.03). Tumour regression grading did not stratify for outcome. Metabolic response was significantly correlated to Ki-67 and p16 expression (rs  = 0.559 and rs  = -0.549, respectively). Multivariate analysis revealed only PERCIST to be correlated to death and recurrence.CONCLUSION: Pre-operative PERCIST assessment of CRCLM was more prognostic than pathologic and CT response assessment. Metabolic non-response correlated with tumour proliferation and loss of tumour suppression.en_US
dc.subjectColorectal cancer liver metastasesen_US
dc.subjectHepatopancreaticobiliary surgeryen_US
dc.subjectSurgical oncologyen_US
dc.subjectTumour metabolismen_US
dc.subjectTumour regressionen_US
dc.subjectTumour response evaluationen_US
dc.titleMetabolic response evaluation for colorectal liver metastases and correlation to pathologic response and tumour markersen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleANZ Journal of Surgeryen_US
dc.identifier.pubmedurihttp://www.ncbi.nlm.nih.gov/pubmed/27452367en_US
dc.identifier.doi10.1111/ans.13680en_US
dc.description.affiliatesAustin Health, Heidelberg, Victoria, Australiaen_US
dc.description.affiliatesDepartment of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen_US
dc.description.affiliatesDepartment of Pathology, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen_US
dc.description.affiliatesOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen_US
dc.description.affiliatesDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-6656-295Xen_US
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.